Enliven Therapeutics, Inc. (ELVN): Total Liabilities
$16.57M
As of 2025-12-31
$15.07M
As of 2026-06-30
+16.9%
3-year compound annual growth
+20.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.57M | +4.1% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $15.91M | -38.7% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $25.96M | +150.3% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $10.37M | +36.2% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $7.62M | +18.9% | 2023-02-10, Balance as of period end |
| 2020-12-31 | $6.41M | +46.2% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $4.38M | n/a | 2021-03-05, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $16.57M | +4.1% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $21.14M | -2.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $16.69M | +20.9% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $161.76M | +37.5% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| Biohaven Ltd. (BHVN) | 2025-12-31 | $399.38M | +108.4% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $37.28M | +90.4% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $27.78M | +192.2% |
Compare ELVN, MPLT, RYTM, ORKA side by side · Screen every company in Pharmaceutical Preparations ↗